RESEARCH ATLAS
← Compound index
COMPOUND RECORD / COGNISTAR

CognistarКогнистар

PerformanceStressRecovery
Source linked
01 / OVERVIEW

About Cognistar

Names in this research collection

Cognistar hydrolysate

One of four separately identified preparations in a blinded rat stroke comparison.

Research background

One of four separately identified preparations in a blinded rat stroke comparison.

What the studies found

Animal research · 2019

Who or what was studiedMale Wistar rats with embolic middle cerebral artery occlusion, 23 initially randomized per arm; early deaths excluded from analysis.

Reported finding

Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly.

Serial functional testing
Cerebrolysin improved outcomes; Cortexin, Cerebrolysat and Cognistar did not show a comparable significant benefitFigure 1. Neurological severity, adhesive removal and foot-fault testing.
Lesion volume
No significant improvement versus saline in any treatment groupFunctional and histological outcomes are separate.
All reported results & study design →
Methods, dose & source notes

Study of multiple preparations · Journal of the Neurological Sciences 398:22–26

Animal ischemia results do not transfer between differently manufactured formulations.

Blinded rat stroke comparison of four peptide preparations ↗

These highlights cover selected studies. Open a source for its methods, reported doses and full context.

Compound class
Brain-derived hydrolysate
Research collection
Actoprotection & occupational pharmacology · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

No human outcomes in the indexed comparison.

Study methods

Animal head-to-head neurological outcomes.

Independent replication

Independent replication is not established in the linked sources.

Source access

Original sources and the exact review scope are linked below.

Safety evidence

The linked experiments do not establish a safe human performance regimen.

Open a topic for the evidence assessment.

More findings, background and history
EVIDENCE REVIEW / 6 OCTOBER 2026

Outstanding review questions

Appraise original methods and replication; keep animal and cell findings separate from unestablished human benefit and safety.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Publication records can share participants. Source counts are not trial counts.

Browse original study records ↗
03 / SOURCE RECORDS

Linked sources

Explore the research map and unresolved leads ↗

2019 · Blinded rat stroke comparison of four peptide preparationsSerial functional testing: Cerebrolysin improved outcomes; Cortexin, Cerebrolysat and Cognistar did not show a comparable significant benefit
2019Animal / experimentalFull text available

Blinded rat stroke comparison of four peptide preparations

· Journal of the Neurological Sciences 398:22–26

Format: Journal of the Neurological Sciences 398:22–26 · Reviewed: Reported methods, results and evidence limitations

L. Zhang et al. · Journal of the Neurological Sciences 398:22–26

Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly.

Findings, study figures and available tables

Reported findings and study design

Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly.

Prospective, randomized and blinded comparisons of saline, Cognistar, Cerebrolysat, Cortexin and Cerebrolysin. Serial neurological testing through day 28.

Dose, route and schedule

Daily intraperitoneal doses for ten days starting four hours after occlusion: Cognistar, Cerebrolysat and Cerebrolysin 2.5 mL/kg each, Cortexin 1.7 mg/kg or saline 1 mL per rat. One methods line repeats Cerebrolysin where the abstract and other sections identify Cerebrolysat.

Protocol source ↗ · Journal of the Neurological Sciences 398:22–26

Reported findings and study figures · Journal of the Neurological Sciences 398:22–26
MeasureResultComparison, timing and statistics
Serial functional testingCerebrolysin improved outcomes; Cortexin, Cerebrolysat and Cognistar did not show a comparable significant benefitFigure 1. Neurological severity, adhesive removal and foot-fault testing.
Lesion volumeNo significant improvement versus saline in any treatment groupFunctional and histological outcomes are separate.

Animal ischemia results do not transfer between differently manufactured formulations.

Source for the extracted data ↗ · Checked 2026-11-09

Population / setting
Male Wistar rats with embolic middle cerebral artery occlusion, 23 initially randomized per arm; early deaths excluded from analysis.
What was checked
Journal of the Neurological Sciences 398:22–26
Limitations & review scope
  • Animal ischemia results do not transfer between differently manufactured formulations.

Source checked 2026-11-09. See the review scope above for the material assessed.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Cerebrolysat research ↗

1 shared source record

Cerebrolysin research ↗

1 shared source record

Cortexin research ↗

1 shared source record

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗